GlassScriptPhysician profile
Christina Wang
NPI 1861016362
$26,299.94
in general payments reported to CMS, 2019-2025
28 companies · $14K in 2025
The $14K reported for 2025 was more than what 99% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $1,004 · 2023: $3,844 · 2024: $7,035 · 2025: $14K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $17K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $8,400 · Education: $272.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $16,624.70 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $8,400.00 |
| Education | $271.52 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Galderma Laboratories, L.P. | $8,206.40 | 2022-2025 | Nemluvio |
| Abbvie INC. | $4,286.65 | 2022-2025 | |
| Genzyme Corporation | $2,140.47 | 2022-2025 | |
| Lilly USA, LLC | $1,476.59 | 2022-2025 | Ebglyss, Taltz, Olumiant |
| Dermavant Sciences, INC. | $1,222.29 | 2023-2024 | Vtama |
| Regeneron Healthcare Solutions, INC. | $1,222.11 | 2022-2025 | Dupixent |
| Amgen INC. | $929.07 | 2022-2025 | Otezla, Otezla |
| Pfizer INC. | $898.16 | 2023-2025 | |
| Ucb, INC. | $884.59 | 2022-2025 | Bimzelx, Cimzia |
| Sun Pharmaceutical Industries INC. | $787.90 | 2022-2025 | Winlevi, Blu-U, Odomzo |
| Janssen Biotech, INC. | $573.27 | 2022-2025 | Tremfya |
| Incyte Corporation | $510.92 | 2022-2025 | Opzelura, Opzelura |
| Arcutis Biotherapeutics, INC. | $449.77 | 2023-2025 | Zoryve |
| Novartis Pharmaceuticals Corporation | $416.56 | 2022-2025 | |
| Leo Pharma INC. | $401.79 | 2024-2025 | Adbry, Anzupgo |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Journey Medical Corporation | $395.42 | 2022-2024 | |
| Verrica Pharmaceuticals INC. | $330.27 | 2023-2025 | Ycanth |
| E.R. Squibb & Sons, L.L.C. | $319.50 | 2023-2025 | Sotyktu |
| Janssen Scientific Affairs, LLC | $260.80 | 2024 | Tremfya |
| Regeneron Pharmaceuticals, INC. | $191.40 | 2025 | Dupixent |
| Organon LLC | $150.20 | 2025 | Vtama |
| Boehringer Ingelheim Pharmaceuticals, INC. | $74.34 | 2023-2024 | Spevigo |
| Lnhc, INC | $44.10 | 2025 | Zelsuvmi |
| Argenx US, INC. | $33.61 | 2023 | Vyvgart Hytrulo |
| Kyowa Kirin, INC. | $29.06 | 2023 | Poteligeo |
| Strata Skin Sciences, INC. | $26.87 | 2023 | Xtrac |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $19.16 | 2025 | Jublia, Cabtreo |
| Botanix Sb INC | $18.67 | 2025 | Sofdra |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christina Wang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.